Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNOSTAR: XELOX + Dostarlimab vs XELOX in Locally Advanced Rectal Cancer
NCT07381777Phase 2Not yet recruiting
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jan 2026
- Primary completion
- Jul 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab in locally advanced rectal cancer (LARC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
dostarlimab
03
Conditions
locally advanced rectal cancer (LARC)
Beyond the preview
Go deeper on NCT07381777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381777.